See more : EVN AG (EVN.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Revvity, Inc. (RVTY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revvity, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Jianpu Technology Inc. (JT) Income Statement Analysis – Financial Results
- Navamedic ASA (NAVA.OL) Income Statement Analysis – Financial Results
- AFT Pharmaceuticals Limited (AFP.AX) Income Statement Analysis – Financial Results
- Genscript Biotech Corporation (GNNSF) Income Statement Analysis – Financial Results
- Padini Holdings Berhad (7052.KL) Income Statement Analysis – Financial Results
Revvity, Inc. (RVTY)
About Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.75B | 3.31B | 5.07B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B | 2.26B | 2.24B | 2.17B | 2.12B | 1.92B | 1.70B | 1.81B | 1.94B | 1.79B | 1.55B | 1.47B | 1.69B | 1.54B | 1.50B | 1.33B | 1.70B | 1.36B | 1.41B | 1.46B | 1.43B | 1.42B | 1.33B | 2.70B | 2.79B | 2.69B | 2.47B | 1.65B | 1.41B | 1.24B | 1.15B | 1.16B |
| Cost of Revenue | 1.21B | 1.32B | 2.22B | 1.67B | 1.49B | 1.44B | 1.18B | 1.10B | 1.24B | 1.23B | 1.19B | 1.15B | 1.07B | 945.72M | 1.03B | 1.11B | 1.06B | 918.29M | 859.30M | 1.01B | 906.27M | 904.10M | 721.73M | 918.43M | 787.30M | 991.30M | 1.04B | 1.01B | 1.01B | 957.80M | 2.30B | 2.39B | 2.31B | 2.14B | 1.35B | 1.11B | 984.00M | 935.30M | 927.90M |
| Gross Profit | 1.54B | 1.99B | 2.85B | 2.11B | 1.40B | 1.34B | 1.07B | 1.01B | 1.02B | 1.00B | 976.97M | 963.21M | 850.58M | 758.63M | 779.79M | 830.11M | 724.74M | 628.07M | 614.54M | 680.55M | 628.95M | 600.88M | 608.33M | 776.84M | 575.80M | 416.60M | 420.70M | 419.50M | 407.00M | 374.80M | 393.20M | 401.50M | 382.00M | 333.50M | 303.80M | 292.00M | 251.90M | 209.80M | 227.20M |
| Gross Profit Ratio | 55.98% | 60.08% | 56.27% | 55.78% | 48.41% | 48.27% | 47.54% | 47.90% | 45.28% | 44.90% | 45.10% | 45.54% | 44.27% | 44.51% | 43.03% | 42.84% | 40.55% | 40.62% | 41.70% | 40.34% | 40.97% | 39.93% | 45.74% | 45.82% | 42.24% | 29.59% | 28.80% | 29.39% | 28.67% | 28.13% | 14.57% | 14.40% | 14.21% | 13.48% | 18.41% | 20.76% | 20.38% | 18.32% | 19.67% |
| Research & Development | 216.58M | 221.62M | 274.97M | 205.39M | 189.34M | 194.00M | 139.40M | 124.28M | 125.93M | 121.14M | 133.02M | 132.64M | 115.82M | 95.41M | 107.25M | 108.06M | 111.62M | 99.72M | 87.37M | 87.05M | 83.15M | 86.45M | 81.32M | 86.12M | 71.20M | 46.00M | 44.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.02B | 1.03B | 1.23B | 917.89M | 815.32M | 811.91M | 616.17M | 600.89M | 598.85M | 659.34M | 585.85M | 632.73M | 628.60M | 490.66M | 504.70M | 522.88M | 444.41M | 376.85M | 365.46M | 387.54M | 386.40M | 431.30M | 411.15M | 418.98M | 327.10M | 226.30M | 243.40M | 290.90M | 284.90M | 278.20M | 234.60M | 242.00M | 223.10M | 195.90M | 179.90M | 169.30M | 151.40M | 133.20M | 130.10M |
| Other Expenses | 0.00 | 25.26M | 36.41M | -23.52M | -27.69M | -13.21M | 33.59M | -3.73M | -4.80M | -5.54M | -14.84M | -2.92M | -3.88M | -2.14M | 0.00 | 0.00 | -15.35M | 1.74M | -1.50M | 28.89M | 25.67M | 23.11M | 0.00 | 87.72M | 66.10M | 50.40M | 44.60M | 40.90M | 39.40M | 36.80M | 37.80M | 36.30M | 33.70M | 29.90M | 25.50M | 24.60M | 21.20M | 16.40M | 15.10M |
| Operating Expenses | 1.24B | 1.25B | 1.50B | 1.12B | 1.00B | 1.01B | 755.57M | 725.16M | 724.78M | 780.48M | 718.87M | 765.37M | 744.42M | 586.07M | 611.95M | 630.95M | 540.69M | 478.31M | 451.33M | 503.48M | 495.22M | 540.87M | 492.46M | 592.81M | 464.40M | 322.70M | 332.90M | 331.80M | 324.30M | 315.00M | 272.40M | 278.30M | 256.80M | 225.80M | 205.40M | 193.90M | 172.60M | 149.60M | 145.20M |
| Cost & Expenses | 2.45B | 2.57B | 3.72B | 2.80B | 2.49B | 2.44B | 1.94B | 1.83B | 1.96B | 2.01B | 1.91B | 1.92B | 1.82B | 1.53B | 1.64B | 1.74B | 1.60B | 1.40B | 1.31B | 1.51B | 1.40B | 1.44B | 1.21B | 1.51B | 1.25B | 1.31B | 1.37B | 1.34B | 1.34B | 1.27B | 2.58B | 2.67B | 2.56B | 2.37B | 1.55B | 1.31B | 1.16B | 1.08B | 1.07B |
| Interest Income | 72.13M | 3.59M | 2.24M | 1.01M | 1.50M | 1.14M | 2.57M | 702.00K | 673.00K | 667.00K | 650.00K | 747.00K | 1.88M | 832.00K | 1.04M | 4.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 98.81M | 103.96M | 102.13M | 49.71M | 63.63M | 66.98M | 43.94M | 41.53M | 38.00M | 36.27M | 49.92M | 45.79M | 24.78M | 15.89M | 17.16M | 82.14M | 41.70M | 0.00 | 0.00 | 47.71M | 105.08M | 279.72M | 128.31M | 74.63M | 7.00M | 0.00 | 64.60M | 8.90M | 0.00 | 121.80M | 12.10M | 0.00 | 900.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 431.77M | 427.00M | 311.44M | 246.51M | 214.03M | 180.59M | 105.00M | 99.97M | 121.48M | 125.26M | 154.94M | 126.87M | 129.26M | 108.96M | 113.11M | 125.10M | 103.50M | 66.84M | 124.38M | 89.51M | 89.78M | 96.11M | 84.26M | 127.26M | 66.10M | 50.40M | 44.60M | 48.20M | 36.00M | 36.80M | 30.50M | 31.10M | 29.70M | 19.90M | 15.00M | 17.70M | 12.20M | 16.40M | 15.10M |
| EBITDA | 713.56M | 1.30B | 1.73B | 1.20B | 609.55M | 518.76M | 424.63M | 405.96M | 378.63M | 322.61M | 331.73M | 223.24M | 200.06M | 267.04M | 200.91M | 262.65M | 264.89M | 219.24M | 287.59M | 266.58M | 223.51M | 156.13M | 200.13M | 311.28M | 177.50M | 82.10M | 166.20M | 135.90M | 118.70M | 168.00M | 151.30M | 154.30M | 154.90M | 127.60M | 113.40M | 115.80M | 91.50M | 57.20M | 79.00M |
| EBITDA Ratio | 25.94% | 36.19% | 34.45% | 32.00% | 20.09% | 18.13% | 20.32% | 18.21% | 18.02% | 15.02% | 17.19% | 15.25% | 11.40% | 15.41% | 14.39% | 16.42% | 15.20% | 14.24% | 24.34% | 15.80% | 17.83% | 14.58% | 21.19% | 18.36% | 17.89% | 5.83% | 11.38% | 9.52% | 8.36% | 12.61% | 5.61% | 5.53% | 5.76% | 5.16% | 6.87% | 8.23% | 7.40% | 5.00% | 6.84% |
| Operating Income | 300.56M | 742.70M | 1.33B | 978.58M | 361.97M | 323.88M | 304.80M | 283.07M | 286.13M | 210.74M | 217.44M | 195.66M | 89.70M | 153.60M | 147.61M | 192.97M | 168.17M | 153.40M | 234.29M | 177.07M | 183.91M | 123.37M | 197.58M | 184.03M | 104.40M | 31.70M | 121.60M | 87.70M | 82.70M | 131.20M | 120.80M | 123.20M | 125.20M | 107.70M | 98.40M | 98.10M | 79.30M | 40.80M | 63.90M |
| Operating Income Ratio | 10.93% | 22.43% | 26.29% | 25.87% | 12.55% | 11.66% | 13.50% | 13.38% | 12.65% | 9.42% | 10.04% | 9.25% | 4.67% | 9.01% | 8.15% | 9.96% | 9.41% | 9.92% | 15.90% | 10.49% | 11.98% | 8.20% | 14.86% | 10.86% | 7.66% | 2.25% | 8.32% | 6.14% | 5.83% | 9.85% | 4.48% | 4.42% | 4.66% | 4.35% | 5.96% | 6.98% | 6.42% | 3.56% | 5.53% |
| Total Other Income/Expenses | -117.59M | -90.86M | -54.88M | 39.09M | -124.83M | -66.20M | 1.10M | -50.51M | -42.12M | 4.60M | -53.76M | -140.50M | -26.77M | -10.78M | -15.79M | -45.61M | -16.88M | -2.67M | -74.29M | -38.33M | -56.39M | -32.87M | -163.43M | -39.54M | -66.50M | 124.30M | -35.80M | -7.30M | 3.40M | -76.90M | 1.10M | -2.10M | -4.90M | -500.00K | 1.40M | -700.00K | 1.70M | 31.50M | 24.70M |
| Income Before Tax | 182.98M | 651.84M | 1.28B | 906.36M | 237.14M | 257.68M | 296.72M | 244.07M | 244.02M | 169.60M | 153.33M | 50.59M | 62.93M | 161.98M | 130.68M | 147.36M | 151.29M | 150.74M | 66.66M | 136.75M | 80.88M | -8.55M | 34.15M | 144.49M | 44.90M | 156.00M | 54.00M | 80.40M | 86.10M | -17.10M | 121.90M | 121.10M | 120.30M | 107.20M | 99.80M | 97.40M | 81.00M | 72.30M | 88.60M |
| Income Before Tax Ratio | 6.65% | 19.68% | 25.26% | 23.96% | 8.22% | 9.28% | 13.15% | 11.54% | 10.79% | 7.58% | 7.08% | 2.39% | 3.28% | 9.50% | 7.21% | 7.61% | 8.46% | 9.75% | 4.52% | 8.10% | 5.27% | -0.57% | 2.57% | 8.52% | 3.29% | 11.08% | 3.70% | 5.63% | 6.07% | -1.28% | 4.52% | 4.34% | 4.47% | 4.33% | 6.05% | 6.93% | 6.55% | 6.31% | 7.67% |
| Income Tax Expense | 3.47M | 129.16M | 347.60M | 178.27M | 9.39M | 20.21M | 139.83M | 28.36M | 31.33M | 8.44M | -12.19M | -17.85M | 62.75M | 26.06M | 37.93M | 21.22M | 17.46M | 32.41M | 128.00K | 38.50M | 25.87M | -4.42M | 34.77M | 58.42M | 16.50M | 54.00M | 23.40M | 25.90M | 31.80M | 15.00M | 42.30M | 33.30M | 39.10M | 33.20M | 29.90M | 28.70M | 25.50M | 27.40M | 32.90M |
| Net Income | 693.09M | 569.18M | 943.16M | 727.89M | 227.56M | 237.93M | 156.89M | 234.30M | 212.43M | 157.78M | 167.21M | 69.94M | 174.00K | 135.92M | 85.60M | 126.41M | 131.69M | 119.58M | 66.53M | 96.04M | 52.96M | -4.14M | -620.00K | 90.52M | 28.40M | 102.00M | 33.70M | 60.20M | 54.30M | -32.10M | 79.60M | 87.80M | 81.20M | 74.00M | 69.90M | 68.70M | 55.50M | 44.90M | 55.70M |
| Net Income Ratio | 25.20% | 17.19% | 18.61% | 19.24% | 7.89% | 8.56% | 6.95% | 11.08% | 9.39% | 7.05% | 7.72% | 3.31% | 0.01% | 7.98% | 4.72% | 6.52% | 7.37% | 7.73% | 4.51% | 5.69% | 3.45% | -0.27% | -0.05% | 5.34% | 2.08% | 7.24% | 2.31% | 4.22% | 3.83% | -2.41% | 2.95% | 3.15% | 3.02% | 2.99% | 4.24% | 4.89% | 4.49% | 3.92% | 4.82% |
| EPS | 5.56 | 4.51 | 8.12 | 6.53 | 2.05 | 2.15 | 1.43 | 2.14 | 1.89 | 1.40 | 1.49 | 0.61 | 0.00 | 1.16 | 0.74 | 1.07 | 1.11 | 0.96 | 0.51 | 0.75 | 0.42 | -0.03 | -0.01 | 0.92 | 0.31 | 1.13 | 0.37 | 0.64 | 0.53 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| EPS Diluted | 5.55 | 4.50 | 8.08 | 6.49 | 2.04 | 2.13 | 1.42 | 2.12 | 1.87 | 1.39 | 1.47 | 0.61 | 0.00 | 1.15 | 0.73 | 1.07 | 1.09 | 0.95 | 0.51 | 0.74 | 0.41 | -0.03 | -0.01 | 0.89 | 0.31 | 1.11 | 0.37 | 0.64 | 0.51 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| Weighted Avg Shares Out | 124.70M | 126.16M | 116.17M | 111.51M | 110.83M | 110.56M | 109.86M | 109.48M | 112.51M | 112.59M | 112.25M | 113.73M | 112.98M | 117.11M | 116.25M | 117.66M | 118.64M | 124.57M | 129.52M | 128.06M | 126.09M | 125.57M | 104.56M | 98.39M | 91.30M | 90.27M | 91.08M | 94.80M | 103.03M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
| Weighted Avg Shares Out (Dil) | 124.81M | 126.43M | 116.67M | 112.09M | 111.50M | 111.53M | 110.86M | 110.31M | 113.32M | 113.74M | 113.50M | 114.86M | 113.86M | 117.98M | 116.59M | 118.69M | 120.81M | 125.88M | 131.43M | 129.79M | 129.17M | 125.57M | 107.83M | 101.71M | 91.30M | 91.89M | 91.08M | 94.80M | 105.98M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
Revvity to Present at BofA Securities 2024 Health Care Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide...
Revvity Unveils a New Era of Automated Tuberculosis Testing
WALTHAM, Mass.--(BUSINESS WIRE)-- #TB--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in...
Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up
Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.
Revvity Signals Software's New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, will launch Signals SynergyTM, a software solution designed to drive greater collaboration, project management, and data exchange between pharmaceutical and biotechnology sponsors with their...
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
Revvity (RVTY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Revvity To Hold Earnings Call on Monday, April 29, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company will host a conference call the same day at 8:00 a.m....
Preliminary Injunction Granted to Enforce Revvity's Rights and Cloud Software Group's Obligations Related to Spotfire Software
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has granted a preliminary injunction compelling Cloud Software Group (CSG) to comply with its contractual obligations under its strategic partner agreements with Revvity, including an order to...
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Revvity's (RVTY) New Launch to Boost Research Productivity
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that it has filed a complaint against Cloud Software Group (CSG) in Massachusetts Superior Court and requested injunctive relief to enforce Revvity's rights and CSG's obligations as a strategic partner. CSG is...
Source: https://incomestatements.info
Category: Stock Reports